[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Worldwide Molecular Diagnostics Market Trends and Drivers, Restraints, and Opportunities 2017-2023

July 2017 | 101 pages | ID: WF7607D8EACEN
Infoholic Research

US$ 3,500.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Global Molecular Diagnostics Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023

Overview: Molecular diagnostics includes the measurement and analysis of nucleic acids, proteins, and metabolites to study the genotypes and occurrence of any biochemical changes in the body. This is mainly used to examine disease occurrence in blood, tissue, or even in the bones. The importance of DNA in defining the vital cellular process has facilitated medical advancements in different disease diagnosis. The detection of cancer and various infectious diseases at an early stage is an important advantage of this technology. The capacity of molecular diagnostics to systematize molecular reactions for the enhancement of the clinical diagnosis has put healthcare in front line.

The market for molecular diagnostics is driven by the increasing prevalence of infectious diseases, growing adoption of point-of-care testing, increasing demand for biomarker-based test, and high growth of the market in emerging countries. The growing significance of companion diagnostics, increased number of M&A, and the increased adoption of DNA probe-based diagnostics are providing market growth opportunities. However, stringent regulatory approval and lack of skilled labors are hampering the market growth.

Market Analysis: The Global Molecular Diagnostics Market is estimated to witness a CAGR of 8.5% during the forecast period 2017–2023. The Molecular Diagnostics market is analyzed based on four segments, namely application, technology, end-users, and regions.

Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America holds the major share of the molecular diagnostics market followed by Europe. Various countries in the Americas are taking initiatives for the elimination of viral hepatitis and the major challenge remains in the diagnosis of this disease. This is providing an opportunity for the manufacturers to enhance their market presence. Asia Pacific is expected to have the fastest growth rate due to the high infectious diseases prevalence, large patient pool, and increasing awareness. This is followed by rest of the world, in terms of the growth rate during the forecast period.

Technology Analysis: Technologically, PCR is the primary technique performed before the start of any molecular diagnostic examination and is the golden standard technique for DNA amplification. Thus, the PCR technique holds the largest share among all the molecular diagnostic techniques. The advantages of microarray technology and its wide application range has made it the fastest growing segment in the market.

Application Analysis: The infectious diseases are the largest application segment in 2016 due to a large number of patients suffering with sexually transmitted diseases (STDs), hepatitis, hospital acquired infection, respiratory infection, pathogen ID detection, and others. The market for oncology is expected to have the fastest growth rate during the forecast period due to its rising prevalence of cancer globally.

Key Players: F. Hoffmann-la Roche, Hologic, Inc, Danaher Corporation, Abbott Laboratories, and Siemens Healthineers Inc. are the key players in the market. Becton Dickenson and Company, Bio-ad Laboratories, Inc, Qiagen NV, bioMerieux S.A, Thermo Fisher Scientific are the other predominate and niche players.

Competitive Analysis: Currently, the PCR market is dominating the global molecular diagnostics market, but a lot of new players are focusing on developing microarray and next-generation sequencing technologies to gain future business opportunities. Significant investments in R&D in this market is seen to develop novel technologies. As a support, many companies are receiving funds to develop advanced technology products from diagnostics associations and other venture capitalists. For instance, in November 2016, QuantuMDx received funding from the Bill & Melinda Gates Foundation to develop the CAPTURE-XT pathogen concentration technology and Q-POC molecular diagnostic platform for rapid low-cost TB detection and drug susceptibility testing (DST).

Benefits: The report provides complete details about the usage and adoption rate of molecular diagnostics in various therapeutic verticals and regions. Thus, the key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are impacting the market growth. Additionally, the report gives complete details about the business opportunities to key stakeholders to expand their business and capture the revenue in these specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:


1 INDUSTRY OUTLOOK

1.1 Industry Overview
1.2 Industry Trends
1.3 PEST Analysis

2 REPORT OUTLINE

2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 MARKET SNAPSHOT

3.1 Total Addressable Market
3.2 Segmented Addressable Market
3.3 Related Markets
  3.3.1 Immunoassays
  3.3.2 Clinical Chemistry

4 MARKET OUTLOOK

4.1 Market Definition – Infoholic Research
4.2 Market Segmentation
4.3 Porter 5(Five) Forces

5 MARKET CHARACTERISTICS

5.1 Milestones in Molecular Diagnostics
5.2 Basic steps of molecular diagnostics
5.3 Market Dynamics
  5.3.1 Drivers
    5.3.1.1 Increasing prevalence of Infectious diseases
    5.3.1.2 Growing adoption of POC testing
    5.3.1.3 Increasing demand for biomarker-based tests
    5.3.1.4 High growth of market in emerging countries
  5.3.2 Opportunities
    5.3.2.1 Growing significance of companion diagnostics
    5.3.2.2 Increased number of Merger and Acquisition
    5.3.2.3 Increased adoption of DNA probe-based diagnostics
  5.3.3 Restraints
    5.3.3.1 Stringent regulatory approvals
    5.3.3.2 Lack of skilled labor
  5.3.4 DRO – Impact Analysis
  5.3.5 Key Stakeholders

6 MARKET SEGMENTATION BY TECHNOLOGY: MARKET SIZE AND ANALYSIS

6.1 Overview
6.2 Polymerase Chain Reaction (PCR)
6.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4 Microarray
6.5 Hybridization
6.6 DNA Sequencing
6.7 Other MDX technology

7 MARKET SEGMENTATION BY APPLICATION: MARKET SIZE AND ANALYSIS

7.1 Overview
7.2 Oncology
7.3 Blood Testing
7.4 Infectious Diseases
7.5 Genetic Testing
7.6 Tissue Typing
7.7 Others

8 END-USER: MARKET SIZE AND ANALYSIS

8.1 Overview
8.2 Hospitals
8.3 Reference Laboratories
8.4 Others

9 REGIONS: MARKET SIZE AND ANALYSIS

9.1 Overview
9.2 North America
  9.2.1 US
9.3 Europe
  9.3.1 UK
  9.3.2 Germany
9.4 APAC
  9.4.1 India
  9.4.2 China
  9.4.3 Japan
9.5 Rest of the World
  9.5.1 Brazil
  9.5.2 Mexico
  9.5.3 Africa

10 COMPETITIVE LANDSCAPE

10.1 Overview

11 VENDOR PROFILES

11.1 F.Hoffmann-La Roche Ltd
  11.1.1 Overview
  11.1.2 Business Unit
  11.1.3 Geographic Presence
  11.1.4 Business Focus
  11.1.5 SWOT Analysis
  11.1.6 Business Strategy
11.2 Abbott Laboratories
  11.2.1 Overview
  11.2.2 Business Unit
  11.2.3 Geographic Presence
  11.2.4 Business Focus
  11.2.5 SWOT Analysis
  11.2.6 Business Strategy
11.3 Siemens Healthineers Inc.
  11.3.1 Overview
  11.3.2 Geographic Presence
  11.3.3 Business Focus
  11.3.4 SWOT Analysis
  11.3.5 Business Strategy
11.4 Danaher Corporation.
  11.4.1 Overview
  11.4.2 Business Unit
  11.4.3 Geographic Presence
  11.4.4 Business Focus
  11.4.5 SWOT Analysis
  11.4.6 Business Strategy
11.5 Hologic Inc.
  11.5.1 Overview
  11.5.2 Business Unit
  11.5.3 Geographic Presence
  11.5.4 Business Focus
  11.5.5 SWOT Analysis
  11.5.6 Business Strategy

12 COMPANIES TO WATCH FOR

12.1 Becton Dickinson and Company
  12.1.1 Overview
12.2 Bio-Rad Laboratories, Inc.
  12.2.1 Overview
12.3 QIAGEN NV
  12.3.1 Overview
12.4 bioMerieux S.A.
  12.4.1 Overview
12.5 ThermoFisher Scientific.
  12.5.1 Overview
Annexure
12.6 Abbreviations

Tables
Table 1 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY APPLICATION, 2016–2023 ($MILLION)
Table 2 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE BY GEOGRAPHY, 2016–2023 ($MILLION)
Table 3 OTHER PROMINENT VENDORS IN THE MARKET
Table 4 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 5 F. HOFFMANN-LA ROCHE.: RECENT DEVELOPMENTS
Table 6 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 7 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
Table 8 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 9 SIEMENS HEALTHINEERS INC.: RECENT DEVELOPMENTS
Table 10 DANAHER CORPORATION: OFFERINGS
Table 11 DANAHER CORPORATION: RECENT DEVELOPMENTS
Table 12 HOLOGIC INC: OFFERINGS
Table 13 HOLOGIC INC.: RECENT DEVELOPMENTS
Table 14 BECTON DICKENSON AND COMPANY: RECENT DEVELOPMENTS
Table 15 BIO-RAD LABORATORIES: RECENT DEVELOPMENTS
Table 16 QIAGEN NV: RECENT DEVELOPMENTS
Table 17 BIOMERIEUX: RECENT DEVELOPMENTS
Table 18 THERMOFISHER SCIENTIFIC: RECENT DEVELOPMENTS

Charts
Chart 1 PEST ANALYSIS OF GLOBAL MOLECULAR DIAGNOSTICS MARKET
Chart 2 RESEARCH METHODOLOGY OF GLOBAL MOLECULAR DIAGNOSTICS MARKET
Chart 3 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE, 2016–2023 ($MILLION)
Chart 4 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY SEGMENTATION
Chart 5 PORTER 5 FORCES ON GLOBAL MOLECULAR DIAGNOSTICS MARKET
Chart 6 MARKET DYNAMICS – DRO ANALYSIS
Chart 7 DRO IMPACT ANALYSIS OF THE GLOBAL MOLECULAR DIAGNOSTICS MARKET
Chart 8 KEY STAKEHOLDERS
Chart 9 GLOBAL MOLECULAR DIAGNOSTICS MARKET: SEGMENTATION BY TECHNOLOGY 2016 (% SHARE)
Chart 10 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY APPLICATION, 2016 (% SHARE)
Chart 11 GLOBAL ONCOLOGY MARKET REVENUE, 2017–2023 ($MILLION)
Chart 12 GLOBAL ONCOLOGY TYPES MARKET SHARE, 2016 (%)
Chart 13 GLOBAL BLOOD TESTING MARKET REVENUE, 2017–2023 ($MILLION)
Chart 14 GLOBAL INFECTIOUS DISEASES MARKET REVENUE, 2017–2023 ($MILLION)
Chart 15 GLOBAL INFECTIOUS DISEASES MARKET SHARE, 2016 (%)
Chart 16 GLOBAL GENETIC TESTING MARKET REVENUE FORECAST, 2017–2023 ($MILLION)
Chart 17 GLOBAL TISSUE TYPING MARKET REVENUE, 2017–2023 ($MILLION)
Chart 18 GLOBAL OTHERS MARKET REVENUE, 2017–2023 ($MILLION)
Chart 19 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY END-USER SEGMENTATION, 2016 (% SHARE)
Chart 20 GLOBAL MOLECULAR DIAGNOSTIC MARKET BY GEOGRAPHICAL SEGMENTATION, 2016 (% SHARE)
Chart 21 GLOBAL MOLECULAR DIAGNOSTIC MARKET BY GEOGRAPHICAL SEGMENTATION, 2023 (% SHARE)
Chart 22 MOLECULAR DIAGNOSTICS MARKET REVENUE IN THE NORTH AMERICA, 2016–2023 ($MILLION)
Chart 23 MOLECULAR DIAGNOSTICS MARKET REVENUE IN EUROPE, 2016–2023 ($MILLION)
Chart 24 MOLECULAR DIAGNOSTICS MARKET REVENUE IN APAC, 2016–2023 ($MILLION)
Chart 25 MOLECULAR DIAGNOSTICS MARKET REVENUE IN REST OF THE WORLD, 2016–2023 ($MILLION)
Chart 26 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT
Chart 27 F. HOFFMANN.LA ROCHE: BUSINESS UNITS
Chart 28 F. HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
Chart 29 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS
Chart 30 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
Chart 31 ABBOTT LABORATORIES.: BUSINESS UNITS
Chart 32 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
Chart 33 ABBOTT LABORATORIES.: SWOT ANALYSIS
Chart 34 SIEMENS HEALTHINEERS INC.: OVERVIEW SNAPSHOT
Chart 35 SIEMENS HEALTHINEERS INC.: GEOGRAPHIC PRESENCE
Chart 36 SIEMENS HEALTHINEERS INC.: SWOT ANALYSIS
Chart 37 DANAHER CORPORATION: OVERVIEW SNAPSHOT
Chart 38 DANAHER CORPORATION: BUSINESS UNITS
Chart 39 DANAHER CORPORATION: GEOGRAPHIC PRESENCE
Chart 40 DANAHER CORPORATION: SWOT ANALYSIS
Chart 41 HOLOGIC INC.: OVERVIEW SNAPSHOT
Chart 42 HOLOGIC INC.: BUSINESS UNITS
Chart 43 HOLOGIC INC.: GEOGRAPHICAL PRESENCE
Chart 44 HOLOGIC INC.: SWOT ANALYSIS


More Publications